Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Authors:

Abstract
No abstract available
Funding Information
  • National Institutes of Health
  • National Cancer Institute (P30 CA008748)

This publication has 27 references indexed in Scilit: